Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642021 | 0.99 | MAOA (0.41) | MAOAMAOBHTR2ACYP19A1FAAH | |
| SCHEMBL5645337 | 0.96 | MAOA (0.40) | MAOAMAOBHTR2ASIGMAR1 | |
| SCHEMBL5641436 | 0.90 | HTR2A (0.37) | MAOAHTR2ACYP19A1CYP2D6 | |
| SCHEMBL6002903 | 0.81 | FAAH (0.46) | FAAHS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL5641607 | 0.80 | CYP1A2 (0.41) | MAOACYP2D6SIGMAR1 | |
| SCHEMBL6002777 | 0.79 | FAAH (0.48) | FAAHS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL2097333 | 0.79 | CES1 (0.39) | MAOAMAOBCYP19A1FAAHS1PR2 | |
| SCHEMBL2096342 | 0.78 | CES1 (0.41) | FAAHS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL2095618 | 0.78 | CES1 (0.41) | FAAHS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL6000698 | 0.76 | FAAH (0.41) | FAAHCES1NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | claimed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | claimed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | GLRA2, CACNG5, GLRB | MAOA 2232/4885MAOB 2177/4885HTR2A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.